Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways plc (Nasdaq: CMPS) generates frequent news as it advances COMP360, its investigational synthetic psilocybin treatment, through late-stage clinical development for serious mental health conditions. The company focuses on treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and its updates often highlight progress in these programs, regulatory interactions, and collaborations related to potential delivery models.
News items for CMPS commonly cover clinical trial milestones, such as Phase 3 results in TRD and the design and initiation of late-stage trials in PTSD. For example, Compass has reported achievement of the primary endpoint in its COMP005 Phase 3 trial in TRD and the U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application for COMP360 in PTSD, enabling a Phase 2b/3 trial. Publications of clinical data in peer-reviewed journals, including results from a Phase 2 PTSD study, are also featured.
Investors and observers can also expect announcements about strategic collaborations with healthcare organizations and clinic networks. These collaborations, including those with Radial Health, Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, and HealthPort, are described as helping to inform how investigational COMP360 treatment might be integrated into various care settings if approved.
Additional CMPS news includes financial results, participation in investor and healthcare conferences, and corporate governance developments such as board appointments. Together, these updates provide context on Compass Pathways’ clinical, regulatory, and operational progress as it pursues evidence-based innovation in mental health. Readers interested in CMPS can use this news feed to follow key developments in the company’s COMP360 programs and broader mental health biotechnology strategy.
Compass Pathways (Nasdaq: CMPS) will host a webinar on January 7, 2026, 10:00–11:30 am ET to discuss commercial preparations for treatment-resistant depression (TRD) and planned late-stage clinical trials for post-traumatic stress disorder (PTSD).
Management and collaboration partners will cover commercial readiness, provider economics for multi-hour treatments, patient care pathways, and the emerging profile of COMP360 in TRD. The company will also outline the planned late-stage program for COMP360 in PTSD and include KOL and industry perspectives.
Speakers include Dr Gary Small, Dr Geoff Grammer, Myriam Barthes, and Dimitri Cavathas. A live audio webcast is available at https://lifescievents.com/event/q0v8tp3/, with a replay accessible for 30 days after the event.
Compass Pathways (Nasdaq: CMPS) management will participate in two December investor conferences: a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, FL on December 2, 2025 at 10:00am ET, and a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York, NY on December 3, 2025 at 1:30pm ET.
A live audio webcast of both events will be available from the company’s Investors “Events” page, with replays accessible for 30 days after each event.
Compass Pathways (Nasdaq: CMPS) confirmed management will participate in the Stifel 2025 Healthcare Conference in New York on Tuesday, November 11, 2025 at 10:40 am ET. A live audio webcast will be available from the Investors > Events page on the company website, and a replay will be accessible for 30 days following the event.
Compass Pathways (Nasdaq: CMPS) reported Q3 2025 results and said it is accelerating commercialization plans for COMP360 in treatment‑resistant depression by 9–12 months after completing enrollment in the second Phase 3 trial (COMP006, n=585) and a positive Type B FDA meeting in Sept 2025 discussing NDA strategy and potential rolling submission.
Key near‑term data milestones: 9‑week COMP006 (Part A) and 26‑week COMP005 (Part B) in Q1 2026, and 26‑week COMP006 (Part B) in early Q3 2026. Cash was $185.9M at Sept 30, 2025, and management expects cash to fund operations into 2027. Q3 net loss was $137.7M driven by a $101.3M non‑cash warrant fair‑value adjustment.
NeuroKaire and Compass Pathways (CMPS) announced an R&D collaboration on Oct 30, 2025 to apply NeuroKaire's AI-powered neural image analysis to study how psychedelic compounds affect neuron structure and connectivity.
The study will use stem cell–derived neurons from people with treatment-resistant depression (TRD) and major depressive disorder (MDD), leveraging a proprietary neuroplasticity marker to compare cellular effects across compounds and link findings to clinical phenotypes.
The collaboration aims to narrow the gap between preclinical models and patient outcomes and to inform precision approaches to psychedelic drug development.
Compass Pathways (Nasdaq: CMPS) appointed Dr. Jeffrey Jonas to its Board of Directors effective immediately and announced the retirement of Thomas Lönngren at the end of December after more than six years of service.
Dr. Jonas brings more than 30 years of pharmaceutical R&D and neuroscience leadership, executive experience at Sage Therapeutics and Shire, current board roles at Generation Bio (GBIO) and Noema Pharma, and an extensive publication record; the company cited his expertise as supportive for potential commercialization of COMP360.
Compass Pathways (Nasdaq: CMPS) will report its third quarter financial results for the period ended September 30, 2025 on November 4, 2025. Management will provide an update on recent developments and host a conference call on November 4, 2025 at 8:00 AM ET (1:00 PM UK). A live webcast will be available at the company events page and will be archived for 30 days.
Investors can access the webcast at: https://events.q4inc.com/attendee/698442687.
Compass Pathways (NASDAQ:CMPS) has published results from its Phase 2 study of COMP360 psilocybin for Post-Traumatic Stress Disorder (PTSD) in the Journal of Psychopharmacology. The study evaluated a single 25mg dose in 22 patients across sites in the U.S. and U.K.
Key findings demonstrate that COMP360 was well-tolerated with no serious adverse events. The treatment showed significant efficacy with 81.8% response rate at week 4 and 77.3% at week 12. Patients experienced substantial symptom improvement, with a 29.9-point reduction in CAPS-5 scores at week 4 and 29.5-point reduction at week 12. Notably, remission rates were 63.6% at week 4 and 54.5% at week 12.
Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in four major investor conferences in September 2025. The company will engage in fireside chat sessions at the Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, H.C. Wainwright Global Investment Conference, and TD Cowen's Novel Mechanisms in Neuropsychiatry & Epilepsy Summit.
All sessions will be available via live audio webcast through the company's investor relations website, with replays accessible for 30 days after each event.
Compass Pathways (NASDAQ:CMPS), a biotechnology company focused on mental health innovation, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The company's management will deliver a presentation on August 12, 2025, at 4:00 PM ET in Boston, MA.
Investors can access the presentation through the "Events" page in the Investors section of Compass's website. The webcast recording will remain available for 30 days after the event.